Nusinersen, developed by Biogen in collaboration with Ionis Pharmaceuticals, is an antisense oligonucleotide that targets the survival motor neuron 2 (SMN2) gene.

Olpasiran, a promising therapeutic agent, is a small interfering RNA (siRNA) developed by Arrowhead Pharmaceuticals.

Rituximab is a chimeric monoclonal antibody that targets the CD20 antigen found on the surface of B cells.

Mirvetuximab soravtansine is an antibody-drug conjugate (ADC) developed by ImmunoGen, Inc., targeting folate receptor alpha (FRα).

Loncastuximab tesirine is an antibody-drug conjugate (ADC) developed by ADC Therapeutics, targeting CD19, a protein that is expressed on the surface of B cells.

Retifanlimab, a groundbreaking therapeutic agent, is a fully humanized monoclonal antibody developed by Incyte Corporation.

Inotuzumab Ozogamicin, also known as Besponsa, is an antibody-drug conjugate (ADC) developed by Pfizer.

Antisense oligonucleotide (ASO) drugs represent a significant branch of the small nucleic acid therapeutic field, functioning as molecules that regulate gene expression through specific binding to mRNA.

Infliximab is a chimeric monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α). Developed by Centocor.

Enfortumab Vedotin-ejfv, also known as Padcev, is an antibody-drug conjugate (ADC) developed by Astellas Pharma and Seattle Genetics.

Enlonstobart, a groundbreaking therapeutic agent, is a fully humanized monoclonal antibody developed by Hangzhou Shangjian Biotechnology Co., Ltd.

Disitamab Vedotin is an antibody-drug conjugate (ADC) developed by Hengrui Medicine, targeting human epidermal growth factor receptor 2 (HER2).